NCT06845722 Combined Effects of Balance and Cognitive Training in Patients With Multiple Sclerosis
| NCT ID | NCT06845722 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Riphah International University |
| Condition | Multiple Sclerosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2025-02-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 42 participants in total. It began in 2024-10-01 with a primary completion date of 2025-02-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multiple sclerosis is a potentially disabling disease of the brain and spinal cord involving the central nervous system. Multiple Sclerosis can cause balance and cognitive impairment in patients, affecting overall quality of life. Balance and cognitive training can effectively improve the overall executive function and mobility in patients with multiple sclerosis.
Eligibility Criteria
Inclusion Criteria: * Age of the patients should be 40-55 years.(20) * Gender: both males and females * Patients with diagnosed multiple sclerosis. * According to MOCA assessment, patients with scoring 21-25 will be included. (Patients with executive function deficits due to Multiple Sclerosis including relapsing-remitting, primary progressive and secondary progressive MS).(21) * Patients feel difficulty in Impaired Balance and walking. * According to the Berg Balance Scale, patients under 21-45 will be included.(22) Exclusion Criteria: * Participants with a history of moderate to severe head injury, stroke and seizures will be excluded(23) * Cognitive impairment due to presence of current or past neurological disorders other than Multiple Sclerosis will be excluded.(23) * Participants with active major psychiatric illness (such as schizophrenia, bipolar disorder or depressive disorder) will be excluded(23) * Patients with history of learning disabilities, severe head trauma, alcohol or drug abuse will be excluded(23)
Contact & Investigator
Sabiha Arshad M.Phill
PRINCIPAL INVESTIGATOR
Riphah International University
Frequently Asked Questions
Who can join the NCT06845722 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 55 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06845722 currently recruiting?
Yes, NCT06845722 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.
Where is the NCT06845722 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT06845722 clinical trial?
NCT06845722 is sponsored by Riphah International University. The principal investigator is Sabiha Arshad M.Phill at Riphah International University. The trial plans to enroll 42 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.